Document is current
Any future updates will be listed below
-
Authors
Oba, Takaaki https://orcid.org/0000-0001-8283-4989
Long, Mark D. https://orcid.org/0000-0003-1120-8176
Keler, Tibor
Marsh, Henry C. https://orcid.org/0000-0001-5637-6013
Minderman, Hans https://orcid.org/0000-0003-4987-9266
Abrams, Scott I. https://orcid.org/0000-0002-8742-4708
Liu, Song
Ito, Fumito https://orcid.org/0000-0002-6866-671X
-
Funding
Funding for this research was provided by:
Uehara Memorial Foundation
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R50CA211108)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA172105)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U24CA232979)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K08CA197966)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA016056)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Melanoma Research Alliance
U.S. Department of Health & Human Services | NIH | National Cancer Institute
- License Information
-
More Information
Article History
Received: 30 March 2020
Accepted: 2 October 2020
First Online: 27 October 2020
Competing interests
: T.K. and H.C.M. are employees of and hold stock and options in Celldex Therapeutics which has clinical stage development programs for Flt3L (CDX-301) and an anti-CD40 mAb (CDX-1140). All other authors have no competing interests to declare.
